Cell Line Development
|
Mycenax specializes in high-quality cell line development, offering end-to-end services from vector construction to GMP cell bank generation, fully compliant with ICH guidelines and global standards. We support early-stage material generation for proof-of-concept studies and preclinical development, as well as tailored solutions for antibody humanization, transient transfection, and stable production cell line establishment to meet diverse project needs. Our RapidMAb™ platform further accelerates this process — enabling efficient cell line development from DNA transfection to Research Cell Bank (RCB) establishment in just 3.5 months. |
Versatile CLD Platform Enables Diverse Biologics Production
|
We have developed streamlined processes across multiple platforms, including cell line generation for CHO and Sp2/0, as well as protein production through transient transfection in HEK cells. Our versatile and robust CLD platform supports the efficient production of diverse biologics. Using imaging data from advanced instruments, we verify monoclonality — with both technologies validated and approved by regulatory authorities. |
|
"Proven expertise in developing over 40 cell lines, achieving titers up to 9 g/L in fed-batch processes across diverse protein types" |
 |
Core Technology to Boost Productivity and Speed
 |
NaxLEAP™ Proprietary Transposon Technology The transposon system NaxLEAP™ employs the transposase enzyme to excise and integrate target genes into active regions e of the genome. Key Advantages:
|
||
 |
Beacon® Optofluidic System Powered by the Beacon® Optofluidic System, this platform accelerates cell line development through precise single-cell analysis and high-throughput screening. Key advantages: • Efficient identification of high producers within 5 days. • On-chip titer assessment for early productivity insight • Image-based clonality verification |
||
 |
Vector Design Platform Our Vector Design Platform optimizes gene expression to enhance both yield and quality, supporting efficient development of complex biologics. Key advantages: • Optimized vector design boosts production yield up to four-fold • Enables efficient development of bi/multi-specific antibodies and recombinant proteins • Reduce impurities and undesired aggregates. • Accelerates development timelines and enhances overall efficiency |
 |
 |
|
Mycenax specializes in high-quality cell line development, offering end-to-end services from vector construction to GMP cell bank generation, fully compliant with ICH guidelines and global standards. We support early-stage material generation for proof-of-concept studies and preclinical development, as well as tailored solutions for antibody humanization, transient transfection, and stable production cell line establishment to meet diverse project needs.
Our RapidMAb™ platform further accelerates this process — enabling efficient cell line development from DNA transfection to Research Cell Bank (RCB) establishment in just 3.5 months. |
Versatile CLD Platform Enables Diverse Biologics Production
|
We have developed streamlined processes across multiple platforms, including cell line generation for CHO and Sp2/0, as well as protein production through transient transfection in HEK cells. Our versatile and robust CLD platform supports the efficient production of diverse biologics. Using imaging data from advanced instruments, we verify monoclonality — with both technologies validated and approved by regulatory authorities. |
|
"Proven expertise in developing over 40 cell lines, achieving titers up to 9 g/L in fed-batch processes across diverse protein types" |
 |
 |
 |
Core Technology to Boost Productivity and Speed
|
|||
|
NaxLEAP™ Proprietary Transposon Technology The transposon system NaxLEAP™ employs the transposase enzyme to excise and integrate target genes into active regions e of the genome. Key Advantages:
|
|||
|
|||
|
Beacon® Optofluidic System Powered by the Beacon® Optofluidic System, this platform accelerates cell line development through precise single-cell analysis and high-throughput screening. Key advantages: • Efficient identification of high producers within 5 days. • On-chip titer assessment for early productivity insight • Image-based clonality verification |
|||
|
|||
|
Vector Design Platform Our Vector Design Platform optimizes gene expression to enhance both yield and quality, supporting efficient development of complex biologics. Key advantages: • Optimized vector design boosts production yield up to four-fold • Enables efficient development of bi/multi-specific antibodies and recombinant proteins • Reduce impurities and undesired aggregates. • Accelerates development timelines and enhances overall efficiency |
|||
|
||
|
|
||